TITLE

Metabolic disease: Mitochondrial uncoupler reverses diabetes

AUTHOR(S)
Crunkhorn, Sarah
PUB. DATE
December 2014
SOURCE
Nature Reviews Drug Discovery;Dec2014, Vol. 13 Issue 12, p885
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the development of insulin resistance and hyperglycaemia which use to treat type 2 diabetes (T2D) by reducing the accumulation of lipids in metabolically sensitive organs. It examines the impact of mitochondrial uncoupler to energy inefficiency and increased energy expenditure for the reduction of intracellular lipid content. It stresses the utilization of niclosamide ethanolamine salt (NEN) for a high-fat diet (HFD) in mice.
ACCESSION #
99713851

 

Related Articles

  • STUDY ON THERAPEUTIC OUTCOME, ATTITUDE AND AWARENESS ABOUT TYPE-2 DIABETES AMONG TYPE-2 DIABETIC FEMALE PATIENTS IN ASEER DIABETIC CENTER. Khan, Noohu Abdulla; Venkatachalam, V. V.; Alavudeen, Sirajudeen S.; Alakhali, Khaled M.; Dhanapal, C. K. // Pharmacie Globale;2014, Vol. 5 Issue 1, p1 

    Type 2 diabetes mellitus (T2DM) is a global epidemic problem. Obesity is the single most important contributor to insulin resistance. Management of diabetes requires lifestyle modification (eg. dietary changes and physical activity) and adherence to other healthful behaviors, such as medication...

  • Type 2 diabetes and cardiovascular diseases: How biomarkers can support more tailored based approaches? Gruson, Damien // Biochemia Medica;2014 Supplement, Vol. 24, pS11 

    The rapid increase in type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) prevalence is alarming, affecting all age groups across most ethno-geographical boundaries. This increased prevalence of T2DM and MetS, which constitutes a health threat to the individual and a major burden for...

  • Emerging Incretin-Based Therapies for Type 2 Diabetes: Incretin Mimetics and DPP-4 Inhibitors. Stonhouse, Anthony; Okerson, Ted; Kendall, David; Maggs, David // Current Diabetes Reviews;2008, Vol. 4 Issue 2, p101 

    Type 2 diabetes is a chronic disease characterized by impaired insulin action, progressive β-cell dysfunction as well as abnormalities in pancreatic α-cell function and postprandial substrate delivery. These pathophysiologic defects result in both persistent and progressive hyperglycemia,...

  • Nutraceuticals as therapeutic agents for holistic treatment of diabetes. Baldi, Ashish; Choudhary, Naveen; Kumar, Sumit // International Journal of Green Pharmacy (Medknow Publications & ;Oct-Dec2013, Vol. 7 Issue 4, p278 

    Nutraceuticals is one of the promising approaches for prevention and treatment of a large number of ailments. Nutrients, herbals and dietary supplements are major constituents of nutraceuticals, which make it instrumental in maintaining health, acting against various diseased conditions and thus...

  • The Relationship between HbA1c, Insulin Resistance and Changes of Insulin Secretion in Indonesian Type 2 Diabetic Subjects. Srihardyastutie A.; Soeatmadji, D. W.; Fatchiyah; Aulanni'am // Advances in Natural & Applied Sciences;Jul2014, Vol. 8 Issue 8, p25 

    Type 2 Diabetes Mellitus (Type 2 DM) is considered as heterogenous metabolic disorder with the common characteristic of elevated blood glucose. The main cause of hyperglycemia in Type 2 DM are impaired of insulin secretion and increased insulin resistance. The HbA1c assay has become the most...

  • The potential effect of vanadium compounds on glucose-6-phosphatase†. Shehzad, Saima // Bioscience Horizons: The National Undergraduate Research Journal;Jan2013, Vol. 6, p1 

    Type 2 diabetes is a major chronic health condition in which hyperglycaemia has significant impact on morbidity and mortality, and its ever-increasing incidence has made the production of therapeutic agents for type 2 diabetes more necessary. Vanadium compounds are known to control...

  • Traditional Medicine in Management of Type 2 Diabetes Mellitus. Rizvi, Syed Ibrahim; Matteucci, Elena; Atukeren, Pinar // Journal of Diabetes Research;2013, p1 

    No abstract available.

  • Emerging treatments in type 2 diabetes: focus on canagliflozin. Rosiak, Marek; Grzeszczak, Susanna; Kosior, Dariusz A.; Postula, Marek // Therapeutics & Clinical Risk Management;2014, Vol. 10, p683 

    Type 2 diabetes mellitus (T2DM) is a prevalent metabolic disorder, which affects more than 300 million people globally. The common effect of uncontrolled diabetes is the state of hyperglycemia, which results from beta-cell dysfunction as well as insulin resistance, which is accompanied with...

  • Evidence for the Gut Microbiota Short-Chain Fatty Acids as Key Pathophysiological Molecules Improving Diabetes. Puddu, Alessandra; Sanguineti, Roberta; Montecucco, Fabrizio; Viviani, Giorgio Luciano // Mediators of Inflammation;2014, Vol. 2014, p1 

    In type 2 diabetes, hyperglycemia, insulin resistance, increased inflammation, and oxidative stress were shown to be associated with the progressive deterioration of beta-cell function and mass. Short-chain fatty acids (SCFAs) are organic fatty acids produced in the distal gut by bacterial...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics